Meglumine antimoniate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Clinical data
Other namesMeglumine antimonate
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
  • Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.004.645 Edit this at Wikidata
Chemical and physical data
Molar massVariable
3D model (JSmol)
  • O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
  • InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 checkY
 ☒NcheckY (what is this?)  (verify)

Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines.[3] It is available in Southern Europe and Latin America but not the United States.[4][5]

Society and culture[edit]

It is manufactured by Aventis[6] and sold as Glucantime in France, and Glucantim in Italy.

See also[edit]


  1. ^ a b c d e f g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
  2. ^ Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20. CS1 maint: discouraged parameter (link)
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20. CS1 maint: discouraged parameter (link)
  5. ^ Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20. CS1 maint: discouraged parameter (link)
  6. ^ Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)

External links[edit]